Company intelligence / Profile preview

Radhanite

Birmingham, West Midlands, United Kingdom

Ownership: Private
Development stage: Other

Overview

Radhanite is a UK-based biotechnology company focused on developing next-generation targeted alpha therapies (TAT) for oncology. A spinout from the University of Birmingham, the company utilizes the Sodium Iodide Symporter (NIS) to deliver alpha-emitting radioisotopes specifically to cancer cells. This approach aims to treat refractory solid tumors, including head and neck cancers, by maximizing radiation dose to the tumor while sparing healthy tissue. Radhanite's technology platform is designed to expand the utility of NIS-mediated therapy beyond traditional thyroid applications.

Therapeutic areas: Oncology
Modalities: Radiopharmaceutical
Industry: Biotech

Partnerships

University of Birmingham

Beyond the preview

Go deeper on Radhanite.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Radhanite.

Explore the full profile